Navigation Links
Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
Date:2/19/2008

in Huntington's

disease patients;

-- Completed the Phase 1 portion of the trial, in which Dimebon was safe

and well tolerated, and the Phase 2 portion remains ongoing;

Hormone-Refractory Prostate Cancer

-- Began an open-label Phase 1-2 clinical trial in hormone-refractory

prostate cancer patients;

-- Reported early, positive data showing encouraging, dose-dependent

reductions in serum prostate-specific antigen (PSA) in our two lowest

dosing groups;

-- Based on these results, received approval to expand the size of the

trial and now expect to enroll approximately 100 patients, including

both chemotherapy naive patients as well as patients who have failed

prior chemotherapy;

Strengthened Management Team and Financial Position

-- Appointed Rohan Palekar, a 16-year marketing executive from Johnson &

Johnson's Centocor division as chief commercial officer to lead

commercialization activities for all of our product candidates;

-- Promoted Michele Bronson, Ph.D., to vice president of regulatory

affairs, to represent Medivation programs to U.S. and international

regulatory agencies, develop regulatory strategies and oversee quality

and project management; and,

-- Entered into a $100 million committed equity line of credit facility

with Azimuth Opportunity, Ltd., which provides access to committed

capital at times and in amounts of Medivation's choosing.

2007 Financial Results and 2008 Financial Outlook

Medivation reported a net loss of $31.7 million for the year ended December 31, 2007, compared to a net loss of $15.4 million in the prior year. The basic and diluted loss per share for 2007 was $(1.14) on 27.9 million weighted average common shares outstanding compared to a basic and diluted loss per share of $(0.63) on 24.2 million weighted average common shares outstand
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
3. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
4. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
5. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
6. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
7. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
8. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
9. Escalon(R) Reports Second Quarter Fiscal 2008 Results
10. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
11. Eklin Medical Reports Record Revenues for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... solution to one of the key challenges in the ... of Sussex physicists. , In a paper published today ... Garraway and colleagues show how to make a new ... Quantum technology devices, such as high-precision sensors and specialised ... of atoms. But the methods for trapping these tiny ...
(Date:10/27/2014)... Ryan Carfley , Managing Partner at ... down with Bryan Hamilton, the publisher of the Triangle Business ... in the Research Triangle region of North Carolina. , Just ... the roundtable include the role of social media in ... balance and the unique role that Millennials play in the ...
(Date:10/27/2014)... The Italian company Roadrunnerfoot ... sell its artificial "lower limb", after the German ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) , ... definitive judgement has arrived: Roadrunnerfoot, the small Italian ... hi-tech prostheses with composite materials, has won against ...
(Date:10/27/2014)... YORK , Oct. 27, 2014 Kalorama ... the recent Ebola concern in the United ... the virus.  The healthcare market researcher said the FDA,s Emergency ... in vitro diagnostic tests for the detection of the ... has proved useful.  Kalorama routinely assess the IVD industry ...
Breaking Biology Technology:Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3
... Inc. (NYSE: CRY ), an implantable biological medical ... it has filed an IDE with the United States ... the purpose of obtaining Pre-Market Approval (PMA) to distribute PerClot ... following traumatic injuries. PerClot is a unique, ...
... EMERYVILLE, Calif., April 4, 2011 Newly proposed ... patient care under healthcare reform closely mirror quality ... the American healthcare system, a MedeAnalytics analysis has ... The quality measure analysis is included ...
... April 4, 2011 Techne Corporation (NASDAQ: ... April 1, 2011, its R&D Systems subsidiary has ... leading developer and manufacturer of innovative ubiquitin-related research ... that facilitate and accelerate basic research and drug ...
Cached Biology Technology:CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 2CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 3CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 4ACO Proposed Rule: Nine out of Ten Quality Measures Mirror Other Quality Reporting Programs 2Techne Corporation Announces Acquisition 2Techne Corporation Announces Acquisition 3Techne Corporation Announces Acquisition 4
(Date:10/28/2014)... Health (NIH) announced awards to expand the Office ... Center for Advancing Translational Sciences (ORDR-NCATS) collaborative Rare ... network, physician scientists at 22 consortia will work ... research and investigate new treatments for patients with ... $29 million in fiscal 2014 funding from NIH. ...
(Date:10/28/2014)... in a novel environment are linked to individual ... experimental study completed at the University of Eastern ... Institute. The study used novel, long-term observations of ... to analyse if behaviours predict the vulnerability to ... enriched hatchery rearing environments. Based on the ...
(Date:10/28/2014)... associated with a lower risk of developing ovarian cancer, ... Anglia (UEA). , Research published today reveals that ... subclasses of dietary flavonoids) significantly decrease their risk of ... death among women. , The research team studied ... and 55 for more than three decades. , ...
Breaking Biology News(10 mins):NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3Fish 'personality' linked to vulnerability to angling 2Tea and citrus products could lower ovarian cancer risk, new UEA research finds 2
... for a University of Alberta paleontology researcher, who after months of ... as a new species of pterosaur, a flying reptile that lived ... stumped when the small piece of jaw bone was first pulled ... A,s paleontology department. "It could have been from a dinosaur, ...
... 4, 2011) − Scientists at the University of Kentucky have ... break up blood clots, speeds up the progress of prion ... plasminogen a promising new target for the development of drugs ... senior author Chongsuk Ryou, a researcher at the UK Sanders-Brown ...
... Lithuania, Jan. 10, 2011 Neurotechnology , ... announced the release of MegaMatcher 4.0 , ... fingerprint, iris, facial and palmprint biometrics in a ... MegaMatcher 4.0, Neurotechnology has incorporated palmprint technology along ...
Cached Biology News:Research identifies drug target for prion diseases, 'mad cow' 2New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK 2New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK 3
... PROTEAN II xi cell, 16 cm, is used ... and proteins in agarose gels. The cell is ... a central cooling core with gaskets, lower buffer ... plates, 4 sandwich clamps, upper buffer dam, casting ...
CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
...
... system uses the Adept CE 4100 high pressure ... dual wavelength detector for added flexibility. ... processing software and interface unit, CE 4901., The ... may also be used with Windows 98 and ...
Biology Products: